# US 2023/0066720 A1 · Novel prodrugs and conjugates of dimethyltryptamine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0066720 A1
- Document ID: US20230066720A1
- Status: Published application
- Kind: A1
- Application number: 17/889,013
- Filed: 2022-08-16
- Published: 2023-03-02
- Earliest claimed: 2021-06-09
- Applicants: ATAI Life Sciences AG
- Inventors: Robert B. PERNI; Glenn SHORT; Srinivasan G. RAO; Tanweer A. KHAN
- Web page: https://patentgrep.com/patent/US20230066720A1

## CPC

- C07D 209/16: Tryptamines
- A61P 25/24: Antidepressants
- C07D 209/08: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C07D 209/12: Radicals substituted by oxygen atoms
- C07D 209/14: Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07F 9/5728: {condensed with carbocyclic rings or carbocyclic ring systems}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R8, R9, X, Y, Z, W, and m are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

## Claims

### Claim 1

A compound of Formula:
wherein R1 and R2 are independently hydrogen, alkyl, or cycloalkyl; or R1 and R2, together with the atoms to which they are attached form a heterocyclic ring;
X, Y, and Z are independently hydrogen, halogen, —O—, —S—, —NRA—, or (P═O)—ORA(—OR′), wherein R′ and RA are independently hydrogen or alkyl;
R3, R4, and R5 are independently absent, hydrogen, alkyl, —(C═O)-alkyl, —(C═O)CHR7, —(C═O)(CH2)n(NH2), —(C)CH(NH2)(CH3), —(C=O)CH(NH2), —(CH2)n(NH)(C═NH), —(C═O)(CH2)n(NH)(C═NH)—NH2, or
L and M are independently alkyl or aryl;
R7 is hydrogen or alkyl;
R9 is hydrogen, alkyl, or halogen;
R11 is a pharmaceutically acceptable cation, hydrogen, deuterium, alkyl, or cycloalkyl; and
n is an integer from 2-7.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the phaiinaceutically acceptable cation is Na+, K+, or NH4+.

### Claim 3 (depends on 1)

The compound of claim 1, of the formula:

### Claim 4 (depends on 1)

The compound of claim 1, of the formula:

### Claim 5 (depends on 1)

The compound of claim 1, of the formula:

### Claim 6 (depends on 1)

The compound of claim 1, of the formula:

### Claim 7

A compound of Formula (VIII):
wherein R1 and R2 are independently hydrogen, alkyl, or cycloalkyl; or R1 and R2, together with the atoms to which they are attached form a heterocyclic ring;
X, Y, and Z are independently hydrogen, halogen, —O—, —S—, —NRA—, or (P═O)-ORA(—OR′), wherein R′ and RA are independently hydrogen or alkyl;
R3, R4, and R5 are independently absent, hydrogen, alkyl, —(C═O)-alkyl, —(C=O)CHR7, —(C═O)(CH2)n(NH2), —(C)CH(NH2)(CH3), —(C═O)CH(NH2), —(CH2)n(NH)(C═NH), —(C═O)(CH2)n(NH)(C═NH)—NH2, or
L and M are independently alkyl or aryl;
R7 is hydrogen or alkyl;
R9 is hydrogen, alkyl, or halogen;
R11 and R17 are independently a pharmaceutically acceptable cation, hydrogen, deuterium, alkyl, cycloalkyl, —or R11 and R12 together with the atoms to which they are attached form a heterocyclic ring, and
n is an inteuer from 2-7.

### Claim 8 (depends on 7)

The compound of claim 7, wherein the pharmaceutically acceptable cation is Na+, K+, or NH4+.
